Europe Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity

August 2020 | 145 pages | ID: E98B9EDCC407EN
GMD Research

Abstracts

Europe digital biomarkers market accounted for $118.0 million in 2019 and will grow by 40.3% annually over 2020-2030 owing to the rising demand for mobile health apps, elevated level of smartphone and wearable technology in healthcare amid COVID-19 epidemic.

Highlighted with 42 tables and 67 figures, this 145-page report “Europe Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe digital biomarkers market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe digital biomarkers market in every aspect of the classification from perspectives of System Component, Therapeutic Area, Application, Development Status, End User, and Country.

Based on System Component, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Data Collection Tools

• Digital Platforms
• Mobile Apps
• Desktop-based Software
• Wearables
• Biosensors

Data Integration Systems

Based on Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Cardiovascular Diseases
Neurodegenerative Disorders

• Parkinson’s Disease
• Multiple Sclerosis
• Alzheimer’s Disease

Sleep and Movement Diseases
Psychiatric Disorders
Chronic Pain
Gastrointestinal Diseases
Diabetes
Respiratory Conditions
Other Diseases

Based on Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Wellness
• Disease Diagnosis
• Personalised Medication
• Drug Discovery and Development

Based on Development Status, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Novel Digital Biomarkers
• Original Digital Biomarkers
• Approved Digital Biomarkers

Based on End User, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Biopharmaceutical Companies & Labs
• Healthcare Providers
• Insurance Payers

Geographically, the following national/local markets are fully investigated:

• Germany
• UK
• France
• Netherlands
• Italy
• Russia
• Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, Spain, Poland, Czech Republic, Slovakia, Hungary, and Romania)

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by System Component, Therapeutic Area, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe digital biomarkers market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):
Actigraph LLC
Akili Interactive Labs
AliveCor Inc
Altoida Inc
Amgen Inc
Bayer AG
Biogen Inc
Cambridge Cognition Plc
Eli Lilly and Company
Evidation Health, Inc.
F. Hoffmann-La Roche Ltd
Fitbit Inc
GlaxoSmithKline Plc
Happify Health
Human API
IXICO Plc
Koninklijke Philips N.V.
Medical Care Corporation
Medopad Ltd
Mindstrong Health
Neurotrack Technology, Inc
Novartis International AG
Pfizer Inc.
Quanterix Corporation
Sanofi S.A.
The Takeda Pharmaceuticals Company Limited
Verily Life Sciences
Winterlight Labs Inc.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF EUROPE MARKET BY SYSTEM COMPONENT

3.1 Market Overview by System Component
3.2 Data Collection Tools
  3.2.1 Digital Platforms
  3.2.2 Mobile Apps
  3.2.3 Desktop-based Software
  3.2.4 Wearables
  3.2.5 Biosensors
3.3 Data Integration Systems

4 SEGMENTATION OF EUROPE MARKET BY THERAPEUTIC AREA

4.1 Market Overview by Therapeutic Area
4.2 Cardiovascular Diseases
4.3 Neurodegenerative Disorders
  4.3.1 Parkinson’s Disease
  4.3.2 Multiple Sclerosis
  4.3.3 Alzheimer’s Disease
4.4 Sleep and Movement Diseases
4.5 Psychiatric Disorders
4.6 Chronic Pain
4.7 Gastrointestinal Diseases
4.8 Diabetes
4.9 Respiratory Conditions
4.10 Other Diseases

5 SEGMENTATION OF EUROPE MARKET BY APPLICATION

5.1 Market Overview by Application
5.2 Wellness
5.3 Disease Diagnosis
5.4 Personalised Medication
5.5 Drug Discovery and Development

6 SEGMENTATION OF EUROPE MARKET BY DEVELOPMENT STATUS

6.1 Market Overview by Development Status
6.2 Novel Digital Biomarkers
6.3 Original Digital Biomarkers
6.4 Approved Digital Biomarkers

7 SEGMENTATION OF EUROPE MARKET BY END USER

7.1 Market Overview by End User
7.2 Biopharmaceutical Companies & Labs
7.3 Healthcare Providers
7.4 Insurance Payers

8 EUROPEAN MARKET 2019-2030 BY COUNTRY

8.1 Overview of European Market
8.2 Germany
8.3 UK
8.4 France
8.5 Netherlands
8.6 Italy
8.7 Russia
8.8 Rest of European Market

9 COMPETITIVE LANDSCAPE

9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
Actigraph LLC
Akili Interactive Labs
AliveCor Inc
Altoida Inc
Amgen Inc
Bayer AG
Biogen Inc
Cambridge Cognition Plc
Eli Lilly and Company
Evidation Health, Inc.
F. Hoffmann-La Roche Ltd
Fitbit Inc
GlaxoSmithKline Plc
Happify Health
Human API
IXICO Plc
Koninklijke Philips N.V.
Medical Care Corporation
Medopad Ltd
Mindstrong Health
Neurotrack Technology, Inc
Novartis International AG
Pfizer Inc.
Quanterix Corporation
Sanofi S.A.
The Takeda Pharmaceuticals Company Limited
Verily Life Sciences
Winterlight Labs Inc.

10 INVESTING IN EUROPE MARKET: RISK ASSESSMENT AND MANAGEMENT

10.1 Risk Evaluation of Europe Market
10.2 Critical Success Factors (CSFs)
Related Reports and Products

List Of Tables

LIST OF TABLES

Table 1. Snapshot of Europe Digital Biomarkers Market, 2019-2030
Table 2. Overview of Traditional and Digital Biomarker Features, Novel Applications, and Published Examples
Table 3. World Smartphone Connections, Average Network Connection Speed for Smartphones and Tablets, 2019-2030
Table 4. World Mobile Data Traffic by Deployment Mode, 2019-2030, EB/year
Table 5. World Mobile Data Traffic by Device, 2019-2030, EB/year
Table 6. Current Challenges of Digital Biomarkers in Medical Settings
Table 7. Main Product Trends and Market Opportunities in Europe Digital Biomarkers Market
Table 8. Europe Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 9. Europe Digital Biomarkers Market: Data Collection Tools by Type, 2019-2030, $ mn
Table 10. Europe Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 11. Europe Digital Biomarkers Market: Neurodegenerative Disorders by Type, 2019-2030, $ mn
Table 12. Europe Digital Biomarkers Market by Application, 2019-2030, $ mn
Table 13. Europe Digital Biomarkers Market by Development Status, 2019-2030, $ mn
Table 14. Europe Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 15. Europe Digital Biomarkers Market by Country, 2019-2030, $ mn
Table 16. Germany Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 17. Germany Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 18. Germany Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 19. UK Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 20. UK Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 21. UK Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 22. France Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 23. France Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 24. France Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 25. Netherlands Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 26. Netherlands Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 27. Netherlands Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 28. Italy Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 29. Italy Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 30. Italy Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 31. Russia Digital Biomarkers Market by System Component, 2019-2030, $ mn
Table 32. Russia Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn
Table 33. Russia Digital Biomarkers Market by End User, 2019-2030, $ mn
Table 34. Digital Biomarkers Market in Rest of Europe by Country, 2019-2030, $ mn
Table 35. Breakdown of Europe Market by Key Vendor, 2019, %
Table 36. Actigraph LLC: Company Snapshot
Table 37. Actigraph LLC: Business Segmentation
Table 38. Actigraph LLC: Product Portfolio
Table 39. Actigraph LLC: Revenue, 2016-2018, $ mn
Table 40. Actigraph LLC: Recent Developments
Table 41. Risk Evaluation for Investing in Europe Market, 2019-2030
Table 42. Critical Success Factors and Key Takeaways

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Europe Digital Biomarkers Market, 2019-2030, $ mn
Figure 6. Category and Relationship of Traditional Biomarkers and Digital Biomarkers
Figure 7. Benefits and Challenges of Digital Biomarkers
Figure 8. Europe Biomarkers Market, 2019-2030, $ mn
Figure 9. Share of Digital Biomarkers in Total Biomarkers Market, 2019-2030
Figure 10. Impact of COVID-19 on Business
Figure 11. Primary Drivers and Impact Factors of Europe Digital Biomarkers Market
Figure 12. World 5G Traffic, 2019-2030, EB/year
Figure 13. Primary Restraints and Impact Factors of Europe Digital Biomarkers Market
Figure 14. Data Security Risk in Various User Groups of Digital Biomarkers
Figure 15. Pathway to Regulatory Approval of Digital Biomarkers
Figure 16. Investment Opportunity Analysis
Figure 17. Porter’s Fiver Forces Analysis of Europe Digital Biomarkers Market
Figure 18. Breakdown of Europe Digital Biomarkers Market by System Component, 2019-2030, % of Revenue
Figure 19. Europe Addressable Market Cap in 2020-2030 by System Component, Value ($ mn) and Share (%)
Figure 20. Europe Digital Biomarkers Market: Data Collection Tools, 2019-2030, $ mn
Figure 21. Europe Digital Biomarkers Market: Digital Platforms, 2019-2030, $ mn
Figure 22. Europe Digital Biomarkers Market: Mobile Apps, 2019-2030, $ mn
Figure 23. Europe Digital Biomarkers Market: Desktop-based Software, 2019-2030, $ mn
Figure 24. Europe Digital Biomarkers Market: Wearables, 2019-2030, $ mn
Figure 25. Europe Digital Biomarkers Market: Biosensors, 2019-2030, $ mn
Figure 26. Europe Digital Biomarkers Market: Data Integration Systems, 2019-2030, $ mn
Figure 27. Breakdown of Europe Digital Biomarkers Market by Therapeutic Area, 2019-2030, % of Sales Revenue
Figure 28. Europe Addressable Market Cap in 2020-2030 by Therapeutic Area, Value ($ mn) and Share (%)
Figure 29. Europe Digital Biomarkers Market: Cardiovascular Diseases, 2019-2030, $ mn
Figure 30. Europe Digital Biomarkers Market: Neurodegenerative Disorders, 2019-2030, $ mn
Figure 31. Europe Digital Biomarkers Market: Parkinson’s Disease, 2019-2030, $ mn
Figure 32. Europe Digital Biomarkers Market: Multiple Sclerosis, 2019-2030, $ mn
Figure 33. Europe Digital Biomarkers Market: Alzheimer’s Disease, 2019-2030, $ mn
Figure 34. Europe Digital Biomarkers Market: Sleep and Movement Diseases, 2019-2030, $ mn
Figure 35. Europe Digital Biomarkers Market: Psychiatric Disorders, 2019-2030, $ mn
Figure 36. Europe Digital Biomarkers Market: Chronic Pain, 2019-2030, $ mn
Figure 37. Europe Digital Biomarkers Market: Gastrointestinal Diseases, 2019-2030, $ mn
Figure 38. Europe Digital Biomarkers Market: Diabetes, 2019-2030, $ mn
Figure 39. Europe Digital Biomarkers Market: Respiratory Conditions, 2019-2030, $ mn
Figure 40. Europe Digital Biomarkers Market: Other Diseases, 2019-2030, $ mn
Figure 41. Breakdown of Europe Digital Biomarkers Market by Application, 2019-2030, % of Sales Revenue
Figure 42. Europe Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)
Figure 43. Europe Digital Biomarkers Market: Wellness, 2019-2030, $ mn
Figure 44. Europe Digital Biomarkers Market: Disease Diagnosis, 2019-2030, $ mn
Figure 45. Europe Digital Biomarkers Market: Personalised Medication, 2019-2030, $ mn
Figure 46. Europe Digital Biomarkers Market: Drug Discovery and Development, 2019-2030, $ mn
Figure 47. Classification of Digital Biomarkers by Development Status
Figure 48. Breakdown of Europe Digital Biomarkers Market by Development Status, 2019-2030, % of Revenue
Figure 49. Europe Addressable Market Cap in 2020-2030 by Development Status, Value ($ mn) and Share (%)
Figure 50. Europe Digital Biomarkers Market: Novel Digital Biomarkers, 2019-2030, $ mn
Figure 51. Europe Digital Biomarkers Market: Original Digital Biomarkers, 2019-2030, $ mn
Figure 52. Europe Digital Biomarkers Market: Approved Digital Biomarkers, 2019-2030, $ mn
Figure 53. Breakdown of Europe Digital Biomarkers Market by End User, 2019-2030, % of Revenue
Figure 54. Europe Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%)
Figure 55. Europe Digital Biomarkers Market: Biopharmaceutical Companies & Labs, 2019-2030, $ mn
Figure 56. Europe Digital Biomarkers Market: Healthcare Providers, 2019-2030, $ mn
Figure 57. Europe Digital Biomarkers Market: Insurance Payers, 2019-2030, $ mn
Figure 58. Breakdown of European Digital Biomarkers Market by Country, 2019 and 2030, % of Revenue
Figure 59. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 60. Digital Biomarkers Market in Germany, 2019-2030, $ mn
Figure 61. Digital Biomarkers Market in UK, 2019-2030, $ mn
Figure 62. Digital Biomarkers Market in France, 2019-2030, $ mn
Figure 63. Digital Biomarkers Market in Netherlands, 2019-2030, $ mn
Figure 64. Digital Biomarkers Market in Italy, 2019-2030, $ mn
Figure 65. Digital Biomarkers Market in Russia, 2019-2030, $ mn
Figure 66. Digital Biomarkers Market in Rest of Europe, 2019-2030, $ mn
Figure 67. Growth Stage of Europe Digital Biomarkers Industry over the Forecast Period


COMPANIES MENTIONED

Actigraph LLC
Akili Interactive Labs
AliveCor Inc
Altoida Inc
Amgen Inc
Bayer AG
Biogen Inc
Cambridge Cognition Plc
Eli Lilly and Company
Evidation Health, Inc.
F. Hoffmann-La Roche Ltd
Fitbit Inc
GlaxoSmithKline Plc
Happify Health
Human API
IXICO Plc
Koninklijke Philips N.V.
Medical Care Corporation
Medopad Ltd
Mindstrong Health
Neurotrack Technology, Inc
Novartis International AG
Pfizer Inc.
Quanterix Corporation
Sanofi S.A.
The Takeda Pharmaceuticals Company Limited
Verily Life Sciences
Winterlight Labs Inc.